1. DIGITAL.CSIC
  2. Biología y Biomedicina
  3. Instituto de Biomedicina de Valencia (IBV)
  4. (IBV) Artículos
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/161677
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE

Comparte tu historia
de Acceso Abierto
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorPérez-Lago, Lauraes_ES
dc.contributor.authorHerranz, Martaes_ES
dc.contributor.authorComas, Iñakies_ES
dc.contributor.authorSierra, Olallaes_ES
dc.contributor.authorBouza, Emilioes_ES
dc.contributor.authorGarcía de Viedma, Daríoes_ES
dc.date.accessioned2018-03-06T09:34:25Z-
dc.date.available2018-03-06T09:34:25Z-
dc.date.issued2016-10-13-
dc.identifier.citationClinical Microbiology and Infection 23(2): 92-97 (2017)es_ES
dc.identifier.issn1198-743X-
dc.identifier.urihttp://hdl.handle.net/10261/161677-
dc.descriptionet al.es_ES
dc.description.abstract[Objective]: Molecular epidemiology techniques in tuberculosis (TB) can identify high-risk strains that are actively transmitted. We aimed to implement a novel strategy to optimize the identification and control of multidrug-resistant (MDR) TB in a specific population. [Methods]: We developed a strain-specific PCR tailored from whole genome sequencing (WGS) data to track a specific MDR prevalent strain in Equatorial Guinea (EG-MDR). [Results]: The PCR was applied prospectively on remnants of GeneXpert reaction mixtures owing to the lack of culture facilities in Equatorial Guinea. In 147 (93%) of 158 cases, we were able to differentiate between infection by the EG-MDR strain or by any other strain and found that 44% of all rifampicin-resistant TB cases were infected by EG-MDR. We also analysed 93 isolates obtained from Equatorial Guinea 15 years ago, before MDR-TB had become the problem it is today. We found that two of the scarce historical MDR cases were infected by EG-MDR. WGS revealed low variability-six single nucleotide polymorphisms acquired by this strain over 15 years-likely because of the lack in the country of a specific program to treat MDR-TB. [Conclusions]: Our novel strategy, which integrated WGS analysis and strain-specific PCRs, represents a low-cost, rapid and transferable strategy that allowed a prospective efficient survey and fast historical analysis of MDR-TB in a population.es_ES
dc.description.sponsorshipThis study was funded by Plan Estatal I+D+I 2013-2016, ISCIII (13/01207; 15/01554) and cofunded by the Fondo Europeo de Desarrollo Regional (FEDER): “Una manera de hacer Europa”. We also received funding from Fondation Merieux (DM/CL/cb15) and a Grant for International Cooperation Projects from the IiSGM (I and II-COOP-INT 2015). L.P. holds a Miguel Servet research grant (CP15/00075), MINECO research grant (SAF2013-43521-R); I.C. holds a European Research Council (ERC) grant (638553-TB-ACCELERATE). Funding was also received from the Spanish Network for Research in Infectious Diseases (REIPI, RD12/0015 to GT).es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2013-43521-Res_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/638553es_ES
dc.relation.isversionofPostprintes_ES
dc.rightsopenAccesses_ES
dc.subjectTuberculosises_ES
dc.subjectMDRes_ES
dc.subjectEquatorial Guineaes_ES
dc.subjectScreeninges_ES
dc.subjectEmergencees_ES
dc.titleA novel strategy based on genomics and specific PCR reveals how a multidrug-resistant Mycobacterium tuberculosis strain became prevalent in Equatorial Guinea 15 years after its emergencees_ES
dc.typeartículoes_ES
dc.identifier.doi10.1016/j.cmi.2016.10.006-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.cmi.2016.10.006es_ES
dc.identifier.e-issn1469-0691-
dc.rights.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.contributor.funderEuropean Research Counciles_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderEuropean Commissiones_ES
dc.relation.csicSíes_ES
oprm.item.hasRevisionno ko 0 false*
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000781es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.cerifentitytypePublications-
Aparece en las colecciones: (IBV) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
2017 Clin Microbiol Infect_vers_Aut.pdf135,88 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

12
checked on 24-abr-2024

WEB OF SCIENCETM
Citations

11
checked on 23-feb-2024

Page view(s)

324
checked on 23-abr-2024

Download(s)

230
checked on 23-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons